Biotech | February 21, 2022
Valneva receives funding for Covid-19 vaccine from Scotland
The grants are expected to be received over the next three years, commencing March 2022
The grants are expected to be received over the next three years, commencing March 2022
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Subscribe To Our Newsletter & Stay Updated
